RMTI (Rockwell Medical) Risk Assessment

View and export this data going back to 1998. Start your Free Trial

What is Rockwell Medical Risk Assessment?

Risk Assessment represents the investment risk of a stock derived from our exclusive method. It suggests how risky the investment opportunity is based on the valuation and the fundamental performance of the stock. It is derived from following key aspects:

1. GuruFocus internally developed valuations of the stock, such as GF valuation.
2. Quality Rank, a business quality indicator developed by GuruFocus.
3. Fundamental performance: Piotroski F-Score, Altman Z-Score, Beneish M-Score, etc.
4. Growth opportunities: 5-year revenue growth rate, 5-Year EPS without NRI Growth Rate, etc.

Value investors are always willing to find undervalued stocks. However, not all the undervalued stocks are good deals, we should also be careful of how risky the investment opportunity is. We believe that if the company's financial strength and profitability are strong, and the stock price is within a reasonable range of the GF valuation, or stock has a high return with its price being undervalued, then it might be a good investment opportunity with low risk.

Based on those aspects listed above, GuruFocus believes the risk assessment of Rockwell Medical is: High Risk: High uncertainty with risk-return tradeoff.

Competitive Comparison of Rockwell Medical's Risk Assessment

For the Drug Manufacturers - Specialty & Generic subindustry, Rockwell Medical's Risk Assessment, along with its competitors' market caps and Risk Assessment data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rockwell Medical's Risk Assessment Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Rockwell Medical's Risk Assessment distribution charts can be found below:

* The bar in red indicates where Rockwell Medical's Risk Assessment falls into.

Save Embed

;

Save Embed

;

Rockwell Medical (NAS:RMTI) Risk Assessment Explanation

Based on the four aspects listed above, GuruFocus provides the following 7 evaluations:

All-in-One Screener Examples (1)
Low Risk: Strong fundamentals, worth long-term holding
Moderate Risk: Sensitive, better choose undervalued stock
High Risk: High uncertainty with risk-return tradeoff
High Risk: Good fundamentals, beware of shrinking business
High Risk: Sensitive to economic or industry trends
High Risk: High uncertainty
No Data: Cannot be evaluated

(1) These are some simple examples. You can access our Risk Assessment filter under All-in-One Screener’s Fundamental tab and set your own criteria.

Rockwell Medical Risk Assessment Related Terms

Thank you for viewing the detailed overview of Rockwell Medical's Risk Assessment provided by GuruFocus.com. Please click on the following links to see related term pages.

Rockwell Medical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Rockwell Medical Inc (NAS:RMTI) » Definitions » Risk Assessment

Comparable Companies

Traded in Other Exchanges

RWMA:Germany

Address

30142 S. Wixom Road, Wixom, MI, USA, 48393

Website

https://www.rockwellmed.com

Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.

Executives

Jesse Neri	officer: SVP, FINANCE	851 DUPORTAIL ROAD, SECOND FLOOR, CHESTERBROOK PA 19087
Mark Strobeck	director, officer: President and CEO	460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Mark H Ravich	other: See Footnote 1
Joan Lau	director	C/O RENOVACOR, INC., 5 MEAD POINT DRIVE, GREENWICH CT 06830
Russell Skibsted	officer: See Remarks	15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Megan C. Timmins	officer: SVP, General Counsel	600 LEE ROAD, SUITE 100, WAYNE PA 19087
Allen Nissenson	director	601 HAWAII ST., EL SEGUNDO CA 90245
Robert S Radie	director	101 LINDENWOOD DRIVE, SUITE 225, MALVERN PA 19355
Andrea Heslin Smiley	director	600 LEE ROAD, SUITE 100, WAYNE PA 19087
David S. Richmond	10 percent owner, other: See Footnote 1	3568 WILDWOOD AVENUE, JACKSON MI 49202
Russell H Ellison	director	270 RIVERSIDE DR., APT. 12D, NEW YORK NY 10025
Marc L Hoffman	officer: Chief Medical Officer	30142 WIXOM ROAD, WIXOM MI 48393
John Peter Mclaughlin	director	C/O PDL BIOPHARMA, INC., 932 SOUTHWOOD BOULEVARD, INCLINE VILLAGE NV 89451
Richmond Brothers, Inc.	10 percent owner, other: See Footnote 1	7415 FOXWORTH COURT, JACKSON MI 49201
Stuart M Paul	director, officer: Chief Executive Officer	HOME DIAGNOSTICS, INC., 2400 NW 55TH COURT, FORT LAUDERDALE FL 33309